Literature DB >> 1198014

Polymyalgia rheumatica and giant cell arteritis: a seven-year survey.

A B Myles.   

Abstract

The seven-year results of all cases (84) diagnosed as polymyalgia rheumatica or giant cell arteritis are reported. The diagnosis proved to be incorrect in seven, of which six had a polyarthritis. Most cases were treated with prednisolone, starting with 20 mg daily for those with evidence of cranial arteritis, and 10 mg for those without. Fourteen patients were withdrawn from treatment (after three months to 31/2 years--mean 21 months), but three relapsed and treatment has been restarted. There was no correlation between the presence or absence of arteritis, the starting dose of prednisolone and the subsequent duration of treatment. A small group (7) received higher doses without obvious advantage. Twenty-two started on 5-9 mg daily, but the dose had to be increased in 13 because of inadequate control of symptoms. Objective physical abnormality, particularly painful limitation of shoulder movement, was present in most cases. No patient developed a serious complication of the disease after treatment had been started. Complications of treatment were infrequent. Spinal osteoporosis occurred in seven, but did not cause long-term disability.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1198014     DOI: 10.1093/rheumatology/14.4.231

Source DB:  PubMed          Journal:  Rheumatol Rehabil        ISSN: 0300-3396


  9 in total

Review 1.  Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

Authors:  V Kyle; B L Hazelman
Journal:  BMJ       Date:  1990-02-10

2.  Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

3.  Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

4.  The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.

Authors:  V Kyle; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

Review 5.  Polymyalgia rheumatica. Its correct diagnosis and treatment.

Authors:  F D Hart
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

Authors:  G Delecoeuillerie; P Joly; A Cohen de Lara; J B Paolaggi
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

7.  Polymyalgia rheumatica and corticosteroids: how much for how long?

Authors:  A R Behn; T Perera; A B Myles
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

Review 8.  Controversies regarding giant cell (temporal, cranial) arteritis.

Authors:  J Eshaghian
Journal:  Doc Ophthalmol       Date:  1979-09-17       Impact factor: 2.379

9.  Prognosis and management of polymyalgia rheumatica.

Authors:  J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.